Skip to main content

Table 2 Phase 2 studies of newer radiosensitizers alone or combined

From: Radiosensitizers in cervical cancer. Cisplatin and beyond

Schedule [ref] # pat Complete R Survival
Gemcitabine 300 mg/m2 (weekly) [95] -- 89% DFS 84%*
OS 100%
Gemcitabine 300–600 mg/m2 days 1, 8, 15, 40, and 47 [96] 19 80% NR
Gemcitabine 300 mg/m2 (weekly) [97] 9 89% DFS 77%**
OS 100%
CDDP 30 mg/m2 + Gemcitabine 20 mg/m2 (both biweekly) [98,99] 37 86% NR***
CDDP 40 mg/m2 + Gemcitabine 125 mg/m2 (both weekly) [100] 36 89% DFS 81%°
CDDP 40 mg/m2 40 Path 55% °°
Vs    
CDDP 40 mg/m2+ Gemcitabine 125 mg/m2 (both arms weekly) [102] 43 Path 77.5%  
CDDP 40 mg/m2 + Gemcitabine 125 mg/m2 both weekly) [104] 20 90% DFS 80%
OS 100%°°°
  1. *Median follow-up 20 months. ** Median follow-up 11 months, trial in patients with renal failure. *** After 3 patients, CDDP was administered weekly. °Median follow-up 14 months. °° Randomized study. Patients underwent radical hysterectomy after EBRT. °°°Median follow-up 12 months.